Veterinary pharmaceutical companies operate in an environment where maintaining product safety requires continuous oversight and specialised expertise. Effective veterinary pharmacovigilance requires marketing authorisation holders to maintain appropriate pharmacovigilance systems, continuously monitor product safety, manage safety information, maintain relevant documentation, and ensure that regulatory responsibilities are fulfilled throughout the lifecycle of veterinary medicinal products.

As portfolios expand and regulatory expectations evolve, managing these responsibilities with limited internal resources can create significant operational pressure. Gaps in expertise, fragmented processes, insufficient oversight, or limited capacity can make it harder to maintain a consistent and well-controlled pharmacovigilance system. Choosing the wrong external partner can add another layer of complexity rather than reducing it.

This is why selecting the right veterinary pharmacovigilance service provider is more than an outsourcing decision—it is a strategic choice that can influence compliance, operational continuity, and the effectiveness of your entire PV system. For companies searching online for best vet pv service providers ranked, the real question is not simply which provider appears at the top of a list, but which partner has the veterinary expertise, regulatory knowledge, quality framework, and service capabilities to support their specific needs.

What should companies do before choosing a veterinary pharmacovigilance service provider?

Before selecting a veterinary pharmacovigilance service provider, companies should first understand what their own pharmacovigilance system requires and where external expertise can add the most value. The starting point is a clear assessment of existing processes, resources, responsibilities, and potential compliance or capacity gaps.

Before approaching potential providers, companies should translate their regulatory obligations into clear operational requirements. This means understanding where internal capabilities are sufficient, where additional expertise is needed, and which activities would benefit from external support. For companies considering veterinary pharmacovigilance outsourcing, the objective should not simply be to transfer individual tasks to an external provider, but to define a service model that complements the company’s existing pharmacovigilance organisation. Before engaging an external provider, companies should therefore:

• define which pharmacovigilance activities will remain in-house and which require external support;
• identify gaps in veterinary expertise, resources, systems, or operational capacity;
• establish clear roles, responsibilities, communication channels, and escalation pathways;
• determine the level of service coverage and continuity required;
• define what a successful external partnership should deliver for the organisation.

Importantly, outsourcing does not transfer the ultimate pharmacovigilance responsibility away from the marketing authorisation holder. Outsourced activities must be clearly defined and controlled, with appropriate contractual arrangements and oversight in place.

By defining these requirements before approaching potential providers, companies can evaluate partners against their actual operational and regulatory needs rather than selecting a provider based on service lists alone.

How Billev Pharma East supports your veterinary pharmacovigilance needs

At Billev Pharma East, we recognise that companies do not all need the same level of veterinary pharmacovigilance support. Some organisations already have established internal capabilities and need specialist expertise in selected areas, while others require a partner able to cover a much broader scope. Our role is to understand what is already in place, identify where additional expertise is needed, and build the right support model around those requirements.

This makes Billev Pharma East more than a provider of individual veterinary PV activities. As a veterinary pharmacovigilance service provider, we bring veterinary, pharmacovigilance, regulatory, and quality expertise together within one organisation. This multidisciplinary approach allows us to understand each client’s requirements in a wider regulatory context and provide support that fits their existing structure rather than treating every pharmacovigilance need as an isolated task.

For clients, this means access to the right expertise without having to build every capability internally. Our support can be adjusted to the client’s existing capabilities, available resources, and required level of external involvement, allowing each organisation to establish a support model that reflects its actual needs.

If you are currently evaluating veterinary PV providers, Billev Pharma East offers the multidisciplinary expertise and flexible support model needed to build a partnership around your actual pharmacovigilance requirements.

What should companies consider when comparing veterinary pharmacovigilance service providers?

When comparing veterinary PV providers, a simple ranking rarely provides enough information to support a well-informed decision. The right partner depends on the company’s portfolio, markets, internal capabilities, regulatory responsibilities, and the level of pharmacovigilance support required.

A meaningful comparison should therefore focus on the capabilities behind the service. Veterinary-specific expertise is particularly important, as the provider should understand the safety considerations associated with veterinary medicinal products and be able to provide access to appropriately qualified professionals. Companies requiring support with QPPV and veterinary pharmacovigilance should also consider whether the provider can ensure the appropriate expertise, availability, and oversight required for their pharmacovigilance system. Regulatory knowledge is equally important, especially where the provider will support activities governed by Veterinary Good Pharmacovigilance Practices (VGVP).Companies should also evaluate how quality is managed in practice. EMA expects marketing authorisation holders to be able to verify the quality of outsourced pharmacovigilance services, the provider’s capacity to perform assigned tasks, and the existence of appropriate quality assurance and quality control systems. Contracted third parties must also accept audits by or on behalf of the MAH.

Beyond technical capability, the right veterinary pharmacovigilance service provider should also fit the organisation operationally. Responsiveness, clear communication, defined responsibilities, sufficient capacity, and continuity of support can all influence the success of a long-term partnership. Companies should therefore assess not only what a provider offers, but how those services will be delivered, governed, and integrated with the internal team.

The scope of specialist expertise should also reflect the company’s specific needs. Where activities such as veterinary signal detection require external support, companies should consider whether the provider has the appropriate scientific expertise and processes to support these activities within the wider pharmacovigilance framework.

What should you verify before appointing a veterinary pharmacovigilance service provider?

Before appointing a veterinary pharmacovigilance service provider, companies should verify how the proposed partnership will work in practice. The scope of outsourced activities, responsibilities of each party, communication pathways, timelines, products covered, quality oversight, and audit arrangements should all be clearly understood before the relationship begins. Where the scope includes specialised activities such as veterinary safety case management, companies should also ensure that responsibilities and interfaces with their internal pharmacovigilance processes are clearly defined.

The contractual framework is particularly important. EMA expects outsourced pharmacovigilance activities and responsibilities to be clearly documented and agreements to address relevant timelines, products covered, subcontracting, audit rights, training, and arrangements for termination where applicable. Clearly defined contractual arrangements help the marketing authorisation holder maintain appropriate oversight and establish accountability for outsourced activities.

Companies should also look beyond the written proposal and understand who will actually support their account, how expertise will be made available, and how issues will be escalated when they arise. A strong provider should be able to explain not only what it can deliver, but how the service will operate once the contract is signed.

Taking these steps before appointment helps companies move from comparing capabilities on paper to evaluating whether a provider can become a reliable part of their pharmacovigilance organisation.

Ready to choose your veterinary pharmacovigilance service provider?

The right veterinary pharmacovigilance service provider should do more than meet a list of technical requirements. A strong partner should fit your organisation, provide access to the expertise you need, and give you confidence in how your outsourced pharmacovigilance activities will be managed.

At Billev Pharma East, we combine veterinary, pharmacovigilance, regulatory, and quality expertise with a flexible approach tailored to each client’s requirements. If you are currently evaluating veterinary PV providers, contact Billev Pharma East to discuss the support your organisation needs.

Frequently asked questions

Sources: 1 – European Medicines Agency (EMA). (2025). Veterinary pharmacovigilance inspections: Q&As. European Medicines Agency, 2 – European Medicines Agency (EMA). (2021). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files. European Medicines Agency, 3 – European Medicines Agency (EMA). (n.d.). Pharmacovigilance system (veterinary medicines). European Medicines Agency, 4 – European Medicines Agency (EMA). (n.d.). Veterinary good pharmacovigilance practices (VGVP). European Medicines Agency, 5 – European Parliament and Council of the European Union. (2018). Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products. Official Journal of the European Union.